Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference65 articles.
1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013;Baccarani;Blood,2013
2. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study;Baccarani;Int. J. Hematol.,2014
3. Long-term follow-up of ponatinib efficacy and safety in patients (pts) with the T315I mutation in the phase 1 and phase 2 (PACE) trials [abstract];Baccarani;Haematologica,2015
4. Bosulif [summary of product characteristics]. Pfizer Limited, Sandwich, United Kingdom, 2017, March 30, 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002373/WC500141721.pdf.
5. Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation;Cornelison;Clin. Lymphoma Myeloma Leuk.,2011
Cited by 35 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Premature senescence and cardiovascular disease following cancer treatments: mechanistic insights;Frontiers in Cardiovascular Medicine;2023-09-14
2. Ponatinib: An update on its drug targets, therapeutic potential and safety;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-09
3. Dose optimisation of ponatinib in chronic phase chronic myeloid leukemia;Expert Review of Hematology;2023-07-27
4. HDAC inhibitor chidamide overcomes drug resistance in chronic myeloid leukemia with the T315i mutation through the Akt–autophagy pathway;Human Cell;2023-05-24
5. Discoidin domain receptor inhibitors as anticancer agents: A systematic review on recent development of DDRs inhibitors, their resistance and structure activity relationship;Bioorganic Chemistry;2023-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3